Independent
Tenure on this board
1.4 yrs
Meeting calendar
ALT · Annual meeting · Thursday, September 25, 2025
Altimmune Inc
10 nominees · 4 ballot items.
Altimmune, Inc. 2025 Annual Meeting includes four proposals: Election of ten directors; Ratification of Ernst & Young LLP as independent registered public accounting firm for 2025; Advisory vote on executive compensation (say-on-pay) for named executive officers; Authorization to adjourn the Annual Meeting to solicit additional proxies if necessary.
Market cap
$613M
1Y TSR
-53.3%
Board grade
C-
Record date
Aug 12, 2025
Filing
DEF 14A
Meeting concluded · Sep 25, 2025
Follow how the vote landed and what changed on Altimmune Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot4
- 1
Election of Directors
ManagementBoard: FORElection of ten nominees to the Board of Directors for terms expiring at the 2026 Annual Meeting of Stockholders.
- 2
RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
ManagementBoard: FORRatify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025.
- 3
ADVISORY VOTE ON EXECUTIVE COMPENSATION
ManagementBoard: FORNon-binding advisory vote to approve the compensation of the Company’s Named Executive Officers as disclosed in the Proxy Statement.
- 4
AUTHORIZATION TO ADJOURN THE ANNUAL MEETING
ManagementBoard: FORAuthorize the adjournment of the Annual Meeting to solicit additional proxies if there are not sufficient votes to approve the foregoing proposals.
Director elections
Nominees on the ballot10
Not independent
Tenure on this board
7.2 yrs
Independent
Tenure on this board
16.5 yrs
Independent
Tenure on this board
22.8 yrs
Independent
Tenure on this board
6.1 yrs
Independent
Tenure on this board
1.4 yrs
Independent
Tenure on this board
7.8 yrs
Also a director at
Oncolytics Biotech Inc (ONCY)
Independent
Tenure on this board
16.3 yrs
Independent
Tenure on this board
9.2 yrs
Independent
Tenure on this board
3.3 yrs
Also a director at
Maze Therapeutics Inc (MAZE)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | STATE STREET CORP | 3.7% | 7,145,550 | $22M |
| 2 | BlackRock, Inc. | 2.9% | 5,726,914 | $18M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2.9% | 5,658,049 | $17M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.8% | 5,382,002 | $17M |
| 5 | BlackRock, Inc. | 2.4% | 4,695,027 | $14M |
| 6 | MARSHALL WACE, LLP | 1.9% | 3,788,403 | $12M |
| 7 | MILLENNIUM MANAGEMENT LLC | 1.7% | 3,258,191 | $10M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.4% | 2,656,914 | $8M |
| 9 | Alyeska Investment Group, L.P. | 1.4% | 2,644,600 | $8M |
| 10 | TWO SIGMA INVESTMENTS, LP | 1.3% | 2,478,900 | $8M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Altimmune Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Xoma Royalty CorpXOMA
Annual meeting·Jul 13, 2026·$533M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Esperion Therapeutics IncESPR
Special meeting·Jul 8, 2026·$814M
Trubridge IncTBRG
Special meeting·Jul 7, 2026·$393M
Reference
Frequently asked questions
- When is the Altimmune Inc 2025 annual meeting?
- Altimmune Inc (ALT) holds its 2025 annual shareholder meeting on Thursday, September 25, 2025.
- What is the record date for the Altimmune Inc 2025 meeting?
- The record date for the Altimmune Inc 2025 meeting is Tuesday, August 12, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Altimmune Inc's 2025 meeting?
- The board is presenting 10 director nominees at the Altimmune Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Altimmune Inc 2025 meeting?
- Shareholders will vote on 4 proposals at the Altimmune Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.